The EUA was issued based on 4 randomized controlled clinical trials that evaluated the efficacy and safety of Actemra in more than 5500 hospitalized patients with COVID-19.
Drugs in the Pipeline
Findings showed that the trial did not meet statistical significance on the primary endpoint.
Investigators evaluated the relationship between atopic dermatitis and frequency of severity markers in patients hospitalized with COVID-19.
Intubation or death, disease worsening similar for tocilizumab, placebo in hospitalized patients.
Dexamethasone appears promising for patients with severe illness.
No significant difference seen in five-, 10-day course for severe COVID-19 without mechanical ventilation.
In patients who were hospitalized with severe coronavirus disease, treatment with lopinavir-ritonavir did not provide a substantial benefit beyond standard care.